Table 1 Main characteristics of the included studies
Trial (author) | Year | N | Treatment arms | Age (years) | Male (%) | Drug regimen | Endpoint |
|---|---|---|---|---|---|---|---|
MEASURE-1 (Baeten) [25] | 2015 | 125 | SEC 150 mg | 40.1 ± 11.6 | 84 (67) | i.v. 10 mg/kg at weeks 0, 2, and 4 and then 150 mg or 75 mg s.c. Q4W starting at week 8. | Primary: ASAS20 (week 16) Secondary: ASAS40 and ASAS partial remission (week 16) |
124 | SEC 75 mg | 42.3 ± 13.2 | 88 (71) | ||||
122 | PBO | 43.1 ± 12.4 | 85 (70) | ||||
MEASURE-2 (Baeten) [25] | 2015 | 72 | SEC 150 mg | 41.9 ± 12.5 | 46 (64) | s.c. 150 mg or 75 mg at weeks 0, 1, 2, 3, and 4 and then every 4 weeks. | Primary: ASAS20 (week 16) Secondary: ASAS40 and ASAS partial remission (week 16) |
73 | SEC 75 mg | 44.4 ± 13.1 | 51 (70) | ||||
74 | PBO | 43.6 ± 13.2 | 56 (76) | ||||
MEASURE-3 (Pavelka) [26] | 2017 | 76 | SEC 300 mg | 42.1 (11.8) | 50 (65.8) | i.v. 10 mg/kg, weeks 0, 2, and 4; 300 mg or 150 mg or matched PBO, s.c. every 4 weeks. | Primary: ASAS20 (week 16) Secondary: ASAS40 and ASAS partial remission (week 16) |
74 | SEC 150 mg | 42.9 (11.1) | 46 (62.2) | ||||
76 | PBO | 42.7 (11.4) | 40 (52.6) | ||||
MEASURE-4 (Kivitz) [27] | 2018 | 116 | Group 1* | 44.5 ± 11.62 | 81 (69.8) | Group 1: s.c. 150 mg SEC load at weeks 0, 1, 2, and 3; group 2: s.c. 150 mg no load. | Primary: ASAS20 (week 16) Secondary: ASAS40 (week 16) |
117 | Group 2†| 41.2 ± 11.07 | 83 (70.9) | ||||
117 | PBO | 43.4 ± 12.46 | 76 (65.0) | ||||
COAST-V (van der Heijde) [28] | 2018 | 83 | IXE Q2W | 41.3 ± 11.2 | 68 (84) | s.c. 80 mg Q2W or Q4W. | Primary: ASAS40 (week 16) Secondary: ASAS20 (week 16) |
81 | IXE Q4W | 41.0 ± 12.1 | 64 (77) | ||||
87 | PBO | 42.7 ± 12.0 | 71 (83) | ||||
COAST-W (Deodhar) [29] | 2019 | 98 | IXE Q2W | 44.2 ± 10.8 | 75 (76.5) | s.c. loading dose (80 mg or 160 mg, respectively) and then 80 mg Q2W or Q4W thereafter. | Primary: ASAS40 (week 16) Secondary: ASAS20 (week 16) |
114 | IXE Q4W | 47.4 ± 13.4 | 91 (79.8) | ||||
104 | PBO | 46.6 ± 12.7 | 87 (83.7) |